TY - JOUR
T1 - Outcome of micropulse laser transscleral cyclophotocoagulation on pediatric versus adult glaucoma patients
AU - Hui Lee, Jun
AU - Shi, Yuhua
AU - Amoozgar, Behzad
AU - Aderman, Christopher
AU - De Alba Campomanes, Alejandra
AU - Lin, Shan
AU - Han, Ying
N1 - Funding Information:
Supported by Research to Prevent Blindness. National Eye Institute, EY00216
Funding Information:
Received for publication May 17, 2017; accepted July 21, 2017. From the *Department of Ophthalmology, University of California, San Francisco School of Medicine, San Francisco, CA; and †Department of Ophthalmology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China. J.H.L. and Y.S. contributed equally. Supported by Research to Prevent Blindness. National Eye Institute, EY00216 Shan Lin is a consultant for Allergan (global headquarters in Dublin, Ireland and US Administrative Headquarters in Parsippany, NJ), Aerie Pharmaceuticals (Irvine, CA and Bedminster, NJ), and ALeyeGN Technologies, LLC (Los Altos, CA). Disclosure: The other authors have no conflict of interest to declare. Reprints: Ying Han, MD, PhD, 10 Koret Street, K-323, P.O. Box 0730, San Francisco, CA 94143-0730 (e-mail: [email protected]). Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/IJG.0000000000000757
Publisher Copyright:
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2017
Y1 - 2017
N2 - Purpose: To study and compare the outcome of micropulse transscelral cyclophotocoagulation in pediatric glaucoma patients to that in adult glaucoma patients. Methods: Consecutive pediatric and adult patients who received micropulse transscelral cyclophotocoagulation between July 2015 and December 2016 at University of California, San Francisco were retrospectively analyzed. All cases had at least 12 months of follow-up. Results: Nine eyes from 9 pediatric patients and 27 eyes from 25 adult patients were included. The sample size in pediatric group is small because MP-TCP was not offered to pediatric patients after unsatisfactory results in initial cases. Preoperatively, the mean intraocular pressure (IOP) was 28.41 ± 8.32 mm Hg in adult patients and 34.28 ± 9.92 mm Hg in pediatric patients. Postoperatively, the mean IOP in adult patients significantly decreased at all follow-up points (P < 0.001). In pediatric patients, the mean IOP decreased to 20.44 ± 13.41 mm Hg at 1 month (P = 0.021), 23.56 ± 10.10 mm Hg at 3 months (P = 0.093), 23.00 ± 8.31 mm Hg (P = 0.018) at 6 months, and 27.20 ± 15.68 mm Hg (P = 0.15) at 12 months. No significant complications were noted in either group. The success rate in adults was 72.22% versus 22.22% in pediatric patients at 12 months (P = 0.02). Seven of 9 pediatric patients required reoperation during the 12 months of follow-up. Conclusions: Micropulse transscelral cyclophotocoagulation is a safe procedure for pediatric as well as adult glaucoma patients. Its effect seems to be short lived in pediatric patients and the rate of reoperation was high.
AB - Purpose: To study and compare the outcome of micropulse transscelral cyclophotocoagulation in pediatric glaucoma patients to that in adult glaucoma patients. Methods: Consecutive pediatric and adult patients who received micropulse transscelral cyclophotocoagulation between July 2015 and December 2016 at University of California, San Francisco were retrospectively analyzed. All cases had at least 12 months of follow-up. Results: Nine eyes from 9 pediatric patients and 27 eyes from 25 adult patients were included. The sample size in pediatric group is small because MP-TCP was not offered to pediatric patients after unsatisfactory results in initial cases. Preoperatively, the mean intraocular pressure (IOP) was 28.41 ± 8.32 mm Hg in adult patients and 34.28 ± 9.92 mm Hg in pediatric patients. Postoperatively, the mean IOP in adult patients significantly decreased at all follow-up points (P < 0.001). In pediatric patients, the mean IOP decreased to 20.44 ± 13.41 mm Hg at 1 month (P = 0.021), 23.56 ± 10.10 mm Hg at 3 months (P = 0.093), 23.00 ± 8.31 mm Hg (P = 0.018) at 6 months, and 27.20 ± 15.68 mm Hg (P = 0.15) at 12 months. No significant complications were noted in either group. The success rate in adults was 72.22% versus 22.22% in pediatric patients at 12 months (P = 0.02). Seven of 9 pediatric patients required reoperation during the 12 months of follow-up. Conclusions: Micropulse transscelral cyclophotocoagulation is a safe procedure for pediatric as well as adult glaucoma patients. Its effect seems to be short lived in pediatric patients and the rate of reoperation was high.
KW - Micropulse laser
KW - Minimally invasive
KW - Pediatric
KW - Transscleral
UR - http://www.scopus.com/inward/record.url?scp=85038129439&partnerID=8YFLogxK
U2 - 10.1097/IJG.0000000000000757
DO - 10.1097/IJG.0000000000000757
M3 - Article
C2 - 28800574
AN - SCOPUS:85038129439
SN - 1057-0829
VL - 26
SP - 936
EP - 939
JO - Journal of Glaucoma
JF - Journal of Glaucoma
IS - 10
ER -